- Article
- Source: Campus Sanofi
- 4 Jun 2025
Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
Present evidence from clinical trials and real-world experience to demonstrate the safety and efficacy of Dupilumab, a biologic targeting the key and central cytokines of Type 2 inflammation, in both upper and lower airway diseases.
MAT-BH-2300373/V1/JUNE 2023